Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

ABSTRACT:

SUBMITTER: Gunawan AS 

PROVIDER: S-EPMC5451352 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature